Clinical study of uric acid urolithiasis

Kaohsiung Journal of Medical Sciences

Volumn 23, Issue 6, 2007, Pages 298-301

  Chou, Yii Her ^a,b   Li, Wei Ming ^b   Li, Ching Chia ^b   Huang, Shu Pin ^a,b   Liu, Chia Chu ^b   Wu, Wen Jeng ^a,b   Hsiao, Hsi Lin ^b   Chang, Tu Hao ^b   Juan, Yung Shun ^c   Su, Chien Yu ^d   Hsu, Hsing ^b   Huang, Chun Hsiung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d Kaohsiung Municipal Min Sheng Hospital   (Taiwan)

Author keywords

Body mass index; Uric acid; Urolithiasis

Indexed keywords

CREATININE; URIC ACID;

ADULT; AGED; ARTICLE; BLADDER STONE; CLINICAL ARTICLE; CLINICAL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERURICEMIA; INFRARED SPECTROPHOTOMETRY; MALE; NEPHROLITHIASIS; PARAMETER; URETER STONE; URINE PH; UROLITHIASIS;

EID: 34447338881     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(09)70412-7     Document Type: Article

References (11)

1. Anderson RA. A complementary approach to urolithiasis prevention. World J Urol 2002;20:294-301.
2. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168:1307-14.
3. Pak CYC, Sakhaee K, Peterson RD, et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int 2001;60:757-61.
4. Pak CYC, Sakhaee K, Moe O, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology 2003;61:523-7.
5. Abate N, Chandalia M, Cabo-Chan AV, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-92.
6. Powell CR, Stoller ML, Schwartz BF, et al. Impact of body weight on urinary electrolytes in urinary stone formers. Urology 2000;55:825-30.
7. Ekeruo WO, Tan YH, Young MD, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 2004;172:159-63.
8. Maalouf NM, Cameron MA, Moe OW, et al. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 2004;13:181-9.
9. Sakhaee K, Adams-Huet B, Moe OW, et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002;62:971-9.
10. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screen cohort. Am J Kidney Dis 2004;44:642-50.
11. Siu YP, Leung KT, Tong MKH, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2005;47:51-9.